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Abstract
Objective: To describe pre- and post-methotrexate (MTX) therapy images from pelvic magnetic
resonance imaging (MRI) with gadopentetate dimeglumine contrast following chemotherapy for
post-partum hemorrhage secondary to placenta increta.
Material and method: A 28-year-old Caucasian female presented 4 weeks post-partum
complaining of intermittent vaginal bleeding. She underwent dilatation and curettage immediately
after vaginal delivery for suspected retained placental tissue but 28 d after delivery, the serum β-
hCG persisted at 156 IU/mL. Office transvaginal sonogram (4 mHz B-mode) was performed,
followed by pelvic MRI using a 1.5 Tesla instrument after administration of gadolinium-based
contrast agent. MTX was administered intramuscularly, and MRI was repeated four weeks later.
Results: While transvaginal sonogram suggested retained products of conception confined to the
endometrial compartment, an irregular 53 × 34 × 28 mm heterogeneous intrauterine mass was
noted on MRI to extend into the anterior myometrium, consistent with placenta increta. Vaginal
bleeding diminished following MTX treatment, with complete discontinuation of bleeding achieved
by ~20 d post-injection. MRI using identical technique one month later showed complete resolution
of the uterine lesion. Serum β-hCG was <5 IU/mL.
Conclusion: Reduction or elimination of risks associated with surgical management of placenta
increta is important to preserve uterine function and reproductive potential. For selected
hemodynamically stable patients, placenta increta may be treated non-operatively with MTX as
described here. A satisfactory response to MTX can be ascertained by serum hCG measurements
with pre- and post-treatment pelvic MRI with gadopentetate dimeglumine enhancement, which
offers advantages over standard transvaginal sonography.
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Introduction
Abnormal placental invasion has traditionally been
treated surgically with definitive diagnosis made at hyster-
ectomy, based on extent of trophoblast extension deter-
mined by microscopic examination. For patients with
placenta increta, non-invasive magnetic resonance imag-
ing (MRI) technology offers a valuable tool for diagnosis
and response to medical therapy. One such treatment is
methotrexate (MTX), a potent folate antagonist proven
useful in management of pathological placenta disorders.
In this report, observations from MRI with gadopentetate
dimeglumine contrast are correlated with clinical features
associated with successful MTX therapy for placenta
increta.
Case report
A 28 year-old Caucasian sought evaluation for intermit-
tent postpartum vaginal bleeding of about one month
duration. Four weeks earlier, she had undergone an
uncomplicated vaginal delivery of a 3100 g female infant.
At delivery the placenta appeared intact and grossly nor-
mal. However, heavy postpartum bleeding required suc-
tion dilation and curettage within one hour of delivery
due to suspected retained placental tissue. The patient was
also placed on 5 mg methergine p.o. every 4 hours. These
interventions reduced the vaginal bleeding and the hemo-
globin was 9.2 g/dl when the patient was discharged
home 48 h later.
At one month post-partum, serum β-hCG level was 156
IU/L. General physical examination revealed no abnor-
malities. Her past medical and gynecologic history were
unremarkable. Her obstetric history was significant for
two spontaneous abortions (1 in 1996 and 1998)
although neither required curettage. A normal spontane-
ous vaginal delivery occurred in 2001, and that postpar-
tum course was remarkable for intermittent hemorrhage
of 8 months' duration. This bleeding eventually necessi-
Fat-saturated post-contrast T1-weighted sagittal MRI demonstrating an enhancing irregular endophytic lesion with anterior  myometrial (M) invasion, secondary to hypervascular placental tissue (arrow) Figure 1
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tated two curettages and hysteroscopic resection of
retained placental tissue. There was no history of any
other pelvic or abdominal instrumentation.
Utilizing a 1.5 Tesla instrument (Intera®, Philips Medical
Systems; Eindhoven, The Netherlands), we obtained fat-
saturated T1-weighted sagittal MRI sequence with 15 mg
intravenous gadopentetate dimeglumine (Magnevist®,
Berlex Inc.; Wayne, NJ USA) contrast enhancement. The
study revealed an irregular 53 × 34 × 28 mm structure in
the anterior myometrium impinging the endometrial cav-
ity and projecting into myometrial tissue extending to
within 5 mm of the anterior serosa (Figure 1). No myo-
mas were noted. These findings agreed with transvaginal
ultrasound (Figure 2) and were consistent with placenta
increta.
The significance of the imaging results was discussed with
the patient, and surgical and non-surgical treatment strat-
egies were presented. Particularly given the patient's wish
to preserve uterine function for future pregnancy, it was
decided to administer 60 mg MTX I.M. after obtaining
informed consent. Hematologic, liver, and renal function
were evaluated and found to be normal before MTX injec-
tion. No untoward effects were experienced following
MTX administration, and vaginal bleeding diminished
gradually over 4 weeks. To avoid further intrauterine
instrumentation (i.e., diagnostic hysteroscopy), follow-up
MRI with identical technique was performed 4 weeks after
MTX therapy to assess treatment response. Complete res-
olution of the uterine lesion was confirmed (Figure 3).
Serial β-hCG was undetectable (<5 IU/mL) ~20 d after
MTX injection.
Transverse intravaginal ultrasound image of uterine corpus showing an irregular mass within the endometrium (arrow) and  apparently normal underlying myometrium (M) Figure 2
Transverse intravaginal ultrasound image of uterine corpus showing an irregular mass within the endometrium (arrow) and 
apparently normal underlying myometrium (M).
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Discussion
Abnormal placental adherence is believed to result from
pathological absence of intervening uterine decidua basa-
lis and fibrinoid layer of Nitabuch. Placental villi are inap-
propriately attached to myometrium in placenta accreta,
invade myometrium in placenta increta, and extend
through the myometrium (beyond uterine serosa) in pla-
centa percreta. The present report describes placenta
increta, a rare but life-threatening complication of preg-
nancy with an estimated incidence of between 1:2500 to
1:1900 gestations [1–3]. More recently, this incidence has
risen with the increased cesarean delivery rate.
Placenta increta is associated with considerable maternal
morbidity and mortality. Indeed, most cases of placenta
increta require hysterectomy to achieve adequate hemos-
tasis [3]. Although hysterectomy remains the definitive
therapy for placenta increta, conservation of the uterus is
desired for future fertility by some women. For this rea-
son, less extreme surgical approaches including wedge
resection of affected myometrium have been proposed as
another method permitting subsequent pregnancy [4].
MTX is a potent antimetabolite, with mechanisms of
action including inhibition of trophoblast cells, reduction
of placental neovascularization, and attenuation of pla-
cental growth factors [5,6].
Our patient's history included known risk factors for pla-
centa increta, including previous abortion, dilatation and
curettage, and manual removal of the placenta. Concur-
rent placenta previa, submucous fibroids, prior cesarean
delivery and multiparity are other recognized risk factors
for placenta increta [7]. Some investigators have found
increased serum alpha-fetoprotein levels, increased serum
Follow-up MRI using identical technique 4 weeks post-MTX therapy, showing normal myometrium (M) and absence of placen- tal tissue (arrow) Figure 3
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β-hCG, and maternal age >35 y to be associated with a
higher frequency of placenta increta [8].
While application of MRI technology in gynecology prac-
tice has been described previously [9], other investigators
have noted the paucity of MRI reports specific to placental
or uterine lesions [10]. We utilized MRI with contrast
enhancement to visualize decidua basalis at the placental
margins [7], since images from standard B-mode transvag-
inal ultrasound suggested only retention of tissue within
the endometrial cavity. The additional information
derived from MRI permitted the diagnostic refinement
needed to counsel the patient appropriately regarding
chemotherapy. For our patient, a satisfactory therapeutic
response to MTX was shown by declining serum hCG lev-
els and confirmed by contrast-enhanced MRI, thus obviat-
ing the need for diagnostic hysteroscopy and possible
hysterectomy.
Conclusion
Placental invasion of the myometrium may be difficult to
discern from routing transvaginal ultrasound, particularly
without optimal color Doppler capability. Accordingly,
utilization of MRI with gadopentetate dimeglumine
enhancement to confirm resolution of abnormal placen-
tation warrants consideration in such clinical settings. The
present case illustrates a successful non-operative manage-
ment strategy for placenta increta utilizing MTX, which
resulted in complete placental resorption as demonstrated
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